Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Gerds A, Gotlib J, Bose P, Deininger M, Dunbar A, Elshoury A, George T, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall A, McMahon B, Mohan S, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder D, Stein B, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward D, Bergman M, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2020, 18: 1248-1269. PMID: 32886902, DOI: 10.6004/jnccn.2020.0042.Peer-Reviewed Original ResearchConceptsMyeloid/lymphoid neoplasmsWHO classificationMLN-EoFusion geneEosinophilic disordersNCCN Clinical Practice GuidelinesRearrangement of PDGFRATyrosine kinaseABL1 rearrangementsClinical practice guidelinesLymphoid neoplasmsNCCN GuidelinesDysregulated tyrosine kinasePeripheral bloodPCM1-JAK2Organ damageABL1 geneNonneoplastic conditionsNeoplasmsEosinophiliaHeterogeneous groupFLT3Practice guidelinesNCCNABL1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply